Lipid-lowering therapy in acute coronary syndromes

JAMA

Volumn 285, Issue 13, 2001, Pages 1758-1760

  Sacks, F M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

DRUG EFFECT; EDITORIAL; ENZYME INHIBITION; HEART MUSCLE ISCHEMIA; HUMAN; LIPID BLOOD LEVEL; PRIORITY JOURNAL; SURVIVAL;

EID: 0035804856     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.13.1758     Document Type: Editorial

References (20)

1. Unstable angina
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandivavian Simvastatin Survival Study (4S)
5. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
6. Clofibrate and niacin in coronary heart disease
7. Early statin treatment following acute myocardial infarction and 1-year survival
8. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
9. Apolipoprotein E deficiency in mice: Gene replacement and prevention of atherosclerosis using adenovirus vectors
10. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein Al
11. Low density lipoprotein independent effects of statins
12. The role of fibric acids in atherosclerosis
13. Biological basis for statin therapy in stroke prevenion
14. Rational and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction
15. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
16. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other societies on coronary prevention
17. Relationship between plasma LDL concentrations during treatment with pravastastin and recurrent coronary events in the Cholesterol and Recurrent Events trial
18. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
19. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet
20. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 3